NCL-240

NCL-240 is a small molecule inhibitor of the phosphatidylinositol-3-kinase (PI3K) pathway, developed as a second-generation analog of DM-PIT-1. It functions by blocking the binding of phosphatidylinositol-3,4,5-triphosphate (PIP3) to Pleckstrin homology (PH) domains, a critical step in the recruitment and activation of Akt and other downstream signaling proteins. To enhance its solubility and therapeutic index, NCL-240 has been formulated into PEG-PE (polyethylene glycol-phosphatidylethanolamine) micelles. Preclinical research has demonstrated its efficacy in inhibiting tumor growth in vivo, particularly in ovarian carcinoma models, and its ability to sensitize TRAIL-resistant cancer cells when delivered in multifunctional micellar preparations.